A

Alpha Cognition Inc
XTSX:ACOG

Watchlist Manager
Alpha Cognition Inc
XTSX:ACOG
Watchlist
Price: 0.24 CAD
Market Cap: 9.9m CAD

Alpha Cognition Inc
Selling, General & Administrative

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Alpha Cognition Inc
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
A
Alpha Cognition Inc
XTSX:ACOG
Selling, General & Administrative
-$3.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Selling, General & Administrative
-$43m
CAGR 3-Years
8%
CAGR 5-Years
-3%
CAGR 10-Years
-14%
Repare Therapeutics Inc
NASDAQ:RPTX
Selling, General & Administrative
-$24.5m
CAGR 3-Years
9%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Selling, General & Administrative
-$109.6m
CAGR 3-Years
17%
CAGR 5-Years
-11%
CAGR 10-Years
-33%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Selling, General & Administrative
-$75.6m
CAGR 3-Years
-35%
CAGR 5-Years
-42%
CAGR 10-Years
-23%
Spectral Medical Inc
TSX:EDT
Selling, General & Administrative
-CA$13.2m
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
-2%
No Stocks Found

Alpha Cognition Inc
Glance View

Market Cap
9.9m CAD
Industry
Biotechnology

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-09-19. The Company’s therapeutic pipeline includes ALPHA-1062 and ALPHA-0602. The Company’s ALPHA-1062 development program is primarily focused on clinical and regulatory development, chemistry, manufacturing and control development, and commercial readiness. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein, and is in preclinical development for the treatment of amyotrophic lateral sclerosis. The company has three development programs: ALPHA-1062 in combination with memantine for the treatment of moderate-to-severe Alzheimer’s; ALPHA-1062 nasal formulation for the treatment of mild traumatic brain injury, and ALPHA-0602, for the treatment of amyotrophic lateral sclerosis. ALPHA-1062 is also being researched as a treatment for mild-traumatic brain injury.

ACOG Intrinsic Value
Not Available
A

See Also

What is Alpha Cognition Inc's Selling, General & Administrative?
Selling, General & Administrative
-3.5m USD

Based on the financial report for Dec 31, 2021, Alpha Cognition Inc's Selling, General & Administrative amounts to -3.5m USD.

What is Alpha Cognition Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 1Y
-269%

Over the last year, the Selling, General & Administrative growth was -269%.

Back to Top